Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

Joseph F. Rizzo III

Tracked across 1 events · 20 articles · First seen Sep 21, 2026 · Last active Sep 22, 2026

Sentiment
0
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 0
Regulatory
Hundreds of patients in the United States have filed personal injury lawsuits against Novo Nordisk and Eli Lilly and Company, alleging that widely used GLP-1 medications including Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity caused a…
Impact: Dr Joseph F. Rizzo III authored a 2024 study linking semaglutide to increased NAION risk, providing a scientific basis for the lawsuits, though he has cautioned against stopping medication based on his findings.
Sep 21, 2026 · 20 articles
ERGEN INTELLIGENCE
Track Joseph F. Rizzo III live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.